A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Inhibition of Autophagy Synergizes Anti-tumor Effect
Interventions: DRUG: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib|DRUG: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University